semaglutide and menopause Weight loss response to in postmenopausal women with without hormone therapy use Compounded Semaglutide for Menopause |

In addition, Asia Pacific is projected to increase in the global GLP-1 agonists market because diabetes and other linked illnesses are becoming more common

Managing weight in the context of diabetes is more challenging, as many diabetes medications promote weight gain and insulin resistance creates metabolic obstacles

FDA review: If trials look good, companies submit data to the FDA

Clinical trials have shown weight reductions of 15-20% of total body weight with certain GLP-1 medications when combined with proper diet and lifestyle habits

Yasuda T, Takeyama Y, Ueda T, Shinzeki M, Sawa H, Nakajima T, et al

Severe Joint Pain: Some patients may experience disabling arthralgia